APA (7th ed.) Citation

Blank, S. V., Christos, P., Curtin, J. P., Goldman, N., Runowicz, C. D., Sparano, J. A., . . . Muggia, F. M. (2010). Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment. Gynecologic oncology, 119(3), 451-456. https://doi.org/10.1016/j.ygyno.2010.08.008

Chicago Style (17th ed.) Citation

Blank, Stephanie V., Paul Christos, John P. Curtin, Noah Goldman, Carolyn D. Runowicz, Joseph A. Sparano, Leonard Liebes, Helen X. Chen, and Franco M. Muggia. "Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment." Gynecologic Oncology 119, no. 3 (2010): 451-456. https://doi.org/10.1016/j.ygyno.2010.08.008.

MLA (9th ed.) Citation

Blank, Stephanie V., et al. "Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment." Gynecologic Oncology, vol. 119, no. 3, 2010, pp. 451-456, https://doi.org/10.1016/j.ygyno.2010.08.008.